Showing 1-8 of 8 "Nervous System Diseases & Disorders"

Status: Enrolling

Investigator: Olga Waln

Study Coordinator: Titilayo Olubajo

Phone: 713.441.3780

This is a multi-center, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 4 weeks (with the exception of subjects on Primidone at baseline who will be allowed 6 weeks of screening to allow for safe ... Read more >

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Julie Baskin

Phone: 713.441.3800

The objective of this study is to evaluate the safety and efficacy of FS VH S/D 500 s-apr for use as an adjunct to sutured dural repair in cranial surgery (NCT02891070). ... Read more >

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Julie Baskin

Phone: 713.441.3800

This is a randomized, active-controlled, multicenter, open-label, parallel groups, Phase 2 study of DSP-7888 Dosing Emulsion plus Bevacizumab versus Bevacizumab alone in patients with recurrent or progressive glioblastoma multiforme (GBM) follow ... Read more >

Status: Open Not Enrolling

Investigator: Richard Klucznik

Study Coordinator: Elmira Ramos

Phone: 713.441.3248

.The primary objective of this study is to demonstrate effectiveness and safety of the NeuroForm Atlas stent system for use with bare metal embolic coils ... Read more >

Status: Enrolling

Investigator: David Chiu

Study Coordinator: Jason Lee

Phone: 713.394.6479

Carotid revascularization for primary prevention of stroke (CREST-2) is two independent multicenter, randomized controlled trials of carotid revascularization and intensive medical management versus medical management alone in patients with asym ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Helga Jones

Phone: 713.363.9388

Purpose The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated. Patients must enter screening at a participating site pr ... Read more >

Status: Enrolling

Investigator: David Baskin

Study Coordinator: Julie Baskin

Phone: 713.441.3800

This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects u ... Read more >

Status: Open Not Enrolling

Investigator: David Baskin

Study Coordinator: Julie Baskin

Phone: 713.441.3800

This is a prospective phase I-II study to assess the efficacy and toxicity of HSV-tk + valacyclovir gene therapy in combination with radiotherapy and standard of care chemotherapy in recurrent anaplastic astrocytoma or glioblastoma multiforme. T ... Read more >